rabbit anti-human foxm1 polyclonal antibody  (Santa Cruz Biotechnology)

Journal: OncoTargets and therapy

Article Title: Expression and functional characterization of FOXM1 in non-small cell lung cancer

doi: 10.2147/OTT.S162523

Figure Lengend Snippet: The FOXM1 protein was detected in NSCLC tissues by immunohistochemistry (×100). Notes: ( A ) FOXM1-positive expression in adenocarcinoma; ( B ) FOXM1-positive expression in squamous cell carcinoma; ( C ) adenocarcinoma without FOXM1 expression; and ( D ) squamous cell carcinoma without FOXM1 expression. Abbreviation: NSCLC, non-small cell lung carcinoma.

Article Snippet: The extracted total protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane, which was subsequently immersed in 5% skim-milk blocking solution for 2 h. The membrane was then incubated with a rabbit anti-human FOXM1 polyclonal antibody and mouse anti-human GAPDH monoclonal antibody (1:1,000; Santa Cruz Biotechnologies, Dallas, TX, USA) separately at 4°C overnight, before being exposed to a secondary antibody at 25°C for 1 h. Finally, chemiluminescence reagent was added.

Techniques: Immunohistochemistry, Expressing

Journal: OncoTargets and therapy

Article Title: Expression and functional characterization of FOXM1 in non-small cell lung cancer

doi: 10.2147/OTT.S162523

Figure Lengend Snippet: The correlations between FOXM1 expression and clinicopathological features in NSCLC patients

Article Snippet: The extracted total protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane, which was subsequently immersed in 5% skim-milk blocking solution for 2 h. The membrane was then incubated with a rabbit anti-human FOXM1 polyclonal antibody and mouse anti-human GAPDH monoclonal antibody (1:1,000; Santa Cruz Biotechnologies, Dallas, TX, USA) separately at 4°C overnight, before being exposed to a secondary antibody at 25°C for 1 h. Finally, chemiluminescence reagent was added.

Techniques: Expressing

Journal: OncoTargets and therapy

Article Title: Expression and functional characterization of FOXM1 in non-small cell lung cancer

doi: 10.2147/OTT.S162523

Figure Lengend Snippet: Univariate analysis of clinicopathological factors for the overall survival in NSCLC patients

Article Snippet: The extracted total protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane, which was subsequently immersed in 5% skim-milk blocking solution for 2 h. The membrane was then incubated with a rabbit anti-human FOXM1 polyclonal antibody and mouse anti-human GAPDH monoclonal antibody (1:1,000; Santa Cruz Biotechnologies, Dallas, TX, USA) separately at 4°C overnight, before being exposed to a secondary antibody at 25°C for 1 h. Finally, chemiluminescence reagent was added.

Techniques: Expressing

Journal: OncoTargets and therapy

Article Title: Expression and functional characterization of FOXM1 in non-small cell lung cancer

doi: 10.2147/OTT.S162523

Figure Lengend Snippet: Survival analysis of 128 NSCLC patients. Notes: ( A ) Differentiation, ( B ) LN metastasis, ( C ) TNM stage, and ( D ) FOXM1 expression. Abbreviations: NSCLC, non-small cell lung carcinoma; LN, lymph node; TNM, tumor-node-metastasis.

Article Snippet: The extracted total protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane, which was subsequently immersed in 5% skim-milk blocking solution for 2 h. The membrane was then incubated with a rabbit anti-human FOXM1 polyclonal antibody and mouse anti-human GAPDH monoclonal antibody (1:1,000; Santa Cruz Biotechnologies, Dallas, TX, USA) separately at 4°C overnight, before being exposed to a secondary antibody at 25°C for 1 h. Finally, chemiluminescence reagent was added.

Techniques: Expressing

Journal: OncoTargets and therapy

Article Title: Expression and functional characterization of FOXM1 in non-small cell lung cancer

doi: 10.2147/OTT.S162523

Figure Lengend Snippet: Univariate and multivariate analyses of prognostic variables for overall survival

Article Snippet: The extracted total protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane, which was subsequently immersed in 5% skim-milk blocking solution for 2 h. The membrane was then incubated with a rabbit anti-human FOXM1 polyclonal antibody and mouse anti-human GAPDH monoclonal antibody (1:1,000; Santa Cruz Biotechnologies, Dallas, TX, USA) separately at 4°C overnight, before being exposed to a secondary antibody at 25°C for 1 h. Finally, chemiluminescence reagent was added.

Techniques: Expressing

Journal: OncoTargets and therapy

Article Title: Expression and functional characterization of FOXM1 in non-small cell lung cancer

doi: 10.2147/OTT.S162523

Figure Lengend Snippet: The FOXM1 expression in NSCLC cell lines and their biological functions. Notes: ( A ) The FOXM1 expression in NSCLC cell lines and normal bronchial epithelial cell line HBE was detected by Western blot (left) and ELISA (right). Western blot ( B ) and ELISA ( C ) verified the efficiency of FOXM1 overexpression and knockdown in NSCLC cell lines. ( D ) The FOXM1 overexpression enhanced proliferation of NSCLC cell lines. ( E ) The FOXM1 overexpression promoted invasion of NSCLC cell lines. (* P <0.05; the t -test was used to contrast quantitative variables between groups). Abbreviations: NSCLC, non-small-cell lung carcinoma; LN, lymph node; TNM, tumor-node-metastasis.

Article Snippet: The extracted total protein was subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred onto a polyvinylidene difluoride membrane, which was subsequently immersed in 5% skim-milk blocking solution for 2 h. The membrane was then incubated with a rabbit anti-human FOXM1 polyclonal antibody and mouse anti-human GAPDH monoclonal antibody (1:1,000; Santa Cruz Biotechnologies, Dallas, TX, USA) separately at 4°C overnight, before being exposed to a secondary antibody at 25°C for 1 h. Finally, chemiluminescence reagent was added.

Techniques: Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Over Expression

Journal: Acta biochimica et biophysica Sinica

Article Title: FoxM1 affects adhesive, migratory, and invasive abilities of human retinoblastoma Y-79 cells by targeting matrix metalloproteinase 2.

doi: 10.1093/abbs/gmz160

Figure Lengend Snippet: Figure 2. Effect of FoxM1 on adhesive and invasive capacity in human retinoblastoma Y-79 cells (A) The effect of transfection with pcDNA3.1-FoxM1, pcDNA3.1 vector, FoxM1 siRNA, or scrambled siRNA on adhesive capacity of Y-79 cells was compared with the negative control group. (B) The effect of transfection with pcDNA3.1-FoxM1, pcDNA3.1 vector, FoxM1 siRNA, or scrambled siRNA on invasive capacity of Y-79 cells was compared with the negative control group. All data were expressed as the mean ± SD of three experiments and each experiment included triplicate repeats. ∗∗P < 0.01 vs negative control.

Article Snippet: The antibodies used were rabbit anti-human polyclonal FoxM1 antibody (sc-376471; Santa Cruz, Dallas, USA), rabbit anti-human polyclonal MMP2 antibody (ab92536; Abcam, Cambridge, USA), rabbit antihuman polyclonal E-cadherin antibody (ab15148; Abcam), rabbit anti-human polyclonal N-cadherin antibody (ab18203; Abcam), rabbit anti-human monoclonal vimentin antibody (ab16700; Abcam), mouse anti-human monoclonal GADPH antibody (ab8245, Abcam), goat anti-mouse IgG-HRP (sc-2031; Santa Cruz), and goat antirabbit IgG-HRP (sc-2004; Santa Cruz).

Techniques: Adhesive, Transfection, Plasmid Preparation, Negative Control

Journal: Acta biochimica et biophysica Sinica

Article Title: FoxM1 affects adhesive, migratory, and invasive abilities of human retinoblastoma Y-79 cells by targeting matrix metalloproteinase 2.

doi: 10.1093/abbs/gmz160

Figure Lengend Snippet: Figure 1. Effect of FoxM1 on EMT and migratory ability in human retinoblastoma Y-79 cells (A) Relative FoxM1 mRNA expression after indicated transfection was analyzed by qRT-PCR. (B) Relative FoxM1 protein expression after indicated transfection was analyzed by a western blot analysis. (C) A wound healing assay was performed in Y-79 cells after indicated transfection. All data were expressed as the mean ± SD of three experiments and each experiment included triplicate repeats. ∗∗P < 0.01 vs negative control.

Article Snippet: The antibodies used were rabbit anti-human polyclonal FoxM1 antibody (sc-376471; Santa Cruz, Dallas, USA), rabbit anti-human polyclonal MMP2 antibody (ab92536; Abcam, Cambridge, USA), rabbit antihuman polyclonal E-cadherin antibody (ab15148; Abcam), rabbit anti-human polyclonal N-cadherin antibody (ab18203; Abcam), rabbit anti-human monoclonal vimentin antibody (ab16700; Abcam), mouse anti-human monoclonal GADPH antibody (ab8245, Abcam), goat anti-mouse IgG-HRP (sc-2031; Santa Cruz), and goat antirabbit IgG-HRP (sc-2004; Santa Cruz).

Techniques: Expressing, Transfection, Quantitative RT-PCR, Western Blot, Wound Healing Assay, Negative Control

Journal: Acta biochimica et biophysica Sinica

Article Title: FoxM1 affects adhesive, migratory, and invasive abilities of human retinoblastoma Y-79 cells by targeting matrix metalloproteinase 2.

doi: 10.1093/abbs/gmz160

Figure Lengend Snippet: Figure 3. FoxM1 regulates the expression of MMP2 in human retinoblastoma Y-79 cells Relative MMP2 expression after transfection with pcDNA3.1-FoxM1 or FoxM1 siRNA was analyzed by qRT-PCR (A) and western blot analysis (B). All data were expressed as the mean ± SD of three experiments and each experiment included triplicate repeats. ∗∗P < 0.01 vs negative control.

Article Snippet: The antibodies used were rabbit anti-human polyclonal FoxM1 antibody (sc-376471; Santa Cruz, Dallas, USA), rabbit anti-human polyclonal MMP2 antibody (ab92536; Abcam, Cambridge, USA), rabbit antihuman polyclonal E-cadherin antibody (ab15148; Abcam), rabbit anti-human polyclonal N-cadherin antibody (ab18203; Abcam), rabbit anti-human monoclonal vimentin antibody (ab16700; Abcam), mouse anti-human monoclonal GADPH antibody (ab8245, Abcam), goat anti-mouse IgG-HRP (sc-2031; Santa Cruz), and goat antirabbit IgG-HRP (sc-2004; Santa Cruz).

Techniques: Expressing, Transfection, Quantitative RT-PCR, Western Blot, Negative Control

Journal: Acta biochimica et biophysica Sinica

Article Title: FoxM1 affects adhesive, migratory, and invasive abilities of human retinoblastoma Y-79 cells by targeting matrix metalloproteinase 2.

doi: 10.1093/abbs/gmz160

Figure Lengend Snippet: Figure 4. FoxM1 binds to and activates the MMP2 promoter (A) The predicted position of the FoxM1 binding site in the −2 kb MMP2 promoter. (B) The different regions in the −2 kb region of MMP2 promoter mediated the transcription activities of FoxM1, as determined by the dual-luciferase reporter assay in HEK293T cells. ∗∗P < 0.01 vs pcDNA3.1 group. (C) The different regions in the −2 kb region of MMP2 promoter mediated the transcription activities of FoxM1, as determined by the dual-luciferase reporter assay in Y-79 cells. ∗∗P < 0.01 vs scrambled siRNA. (D) Direct binding of FoxM1 to the MMP2 promoter region was determined by the ChIP assay. All data were expressed as the mean ± SD of three experiments and each experiment included triplicate repeats.

Article Snippet: The antibodies used were rabbit anti-human polyclonal FoxM1 antibody (sc-376471; Santa Cruz, Dallas, USA), rabbit anti-human polyclonal MMP2 antibody (ab92536; Abcam, Cambridge, USA), rabbit antihuman polyclonal E-cadherin antibody (ab15148; Abcam), rabbit anti-human polyclonal N-cadherin antibody (ab18203; Abcam), rabbit anti-human monoclonal vimentin antibody (ab16700; Abcam), mouse anti-human monoclonal GADPH antibody (ab8245, Abcam), goat anti-mouse IgG-HRP (sc-2031; Santa Cruz), and goat antirabbit IgG-HRP (sc-2004; Santa Cruz).

Techniques: Binding Assay, Luciferase, Reporter Assay

Journal: Acta biochimica et biophysica Sinica

Article Title: FoxM1 affects adhesive, migratory, and invasive abilities of human retinoblastoma Y-79 cells by targeting matrix metalloproteinase 2.

doi: 10.1093/abbs/gmz160

Figure Lengend Snippet: Figure 5. MMP2 knockdown attenuates cell metastasis induced by FoxM1 in human retinoblastoma Y-79 cells Cells were co-transfected with pcDNA3.1- FoxM1 plasmid (pcDNA3.1 vector as negative control) and/or MMP2 siRNA (scrambled siRNA as negative control). (A) The expressions of EMT-related proteins were analyzed by a western blot analysis. (B) The migratory capacity of Y-79 cells was analyzed by the wound healing assay. (C) The adhesive capacity of Y-79 cells was analyzed by the adhesion assay. (D) The invasive capacity of Y-79 cells was analyzed by the invasion assay. All data were expressed as the mean ± SD of three experiments and each experiment included triplicate repeats. ∗∗P < 0.01 vs pcDNA3.1 vector + scrambled siRNA group; ##P < 0.01 vs pcDNA3.1-FoxM1 + scrambled siRNA group.

Article Snippet: The antibodies used were rabbit anti-human polyclonal FoxM1 antibody (sc-376471; Santa Cruz, Dallas, USA), rabbit anti-human polyclonal MMP2 antibody (ab92536; Abcam, Cambridge, USA), rabbit antihuman polyclonal E-cadherin antibody (ab15148; Abcam), rabbit anti-human polyclonal N-cadherin antibody (ab18203; Abcam), rabbit anti-human monoclonal vimentin antibody (ab16700; Abcam), mouse anti-human monoclonal GADPH antibody (ab8245, Abcam), goat anti-mouse IgG-HRP (sc-2031; Santa Cruz), and goat antirabbit IgG-HRP (sc-2004; Santa Cruz).

Techniques: Knockdown, Transfection, Plasmid Preparation, Negative Control, Western Blot, Wound Healing Assay, Adhesive, Cell Adhesion Assay, Invasion Assay

Journal: Acta biochimica et biophysica Sinica

Article Title: FoxM1 affects adhesive, migratory, and invasive abilities of human retinoblastoma Y-79 cells by targeting matrix metalloproteinase 2.

doi: 10.1093/abbs/gmz160

Figure Lengend Snippet: Figure 6. The proposed mechanism for the effect FoxM1 on human retinoblas- toma Y-79 cell metastasis FoxM1 attenuates adhesive and increases migra- tory and invasive capacity of human retinoblastoma Y-79 cells by targeting matrix metalloproteinase 2.

Article Snippet: The antibodies used were rabbit anti-human polyclonal FoxM1 antibody (sc-376471; Santa Cruz, Dallas, USA), rabbit anti-human polyclonal MMP2 antibody (ab92536; Abcam, Cambridge, USA), rabbit antihuman polyclonal E-cadherin antibody (ab15148; Abcam), rabbit anti-human polyclonal N-cadherin antibody (ab18203; Abcam), rabbit anti-human monoclonal vimentin antibody (ab16700; Abcam), mouse anti-human monoclonal GADPH antibody (ab8245, Abcam), goat anti-mouse IgG-HRP (sc-2031; Santa Cruz), and goat antirabbit IgG-HRP (sc-2004; Santa Cruz).

Techniques: Adhesive

Journal: Scientific Reports

Article Title: FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression

doi: 10.1038/s41598-018-38017-0

Figure Lengend Snippet: Correlations between FOXM1 and TYMS in CRC. ( A ) Representative photographs of FOXM1 and TYMS, staining in human CRC tissue showing close similarity in protein expression patterns. Cytoplasmic FOXM1 expression levels were directly correlated with the TYMS expression in the TMA (p = 0.008, r = 0.314). The images above were taken from the A1, C8 and B12 cores: ( B ) SRB assay shows the average cell viability of colon cancer cells. HCT116, DLD1, and HT29 colon cancer cells were treated with 5-FU, ranging from 0 to 100 µg/ml for 72 h. IC50 values were: HCT116 0.6 ± 0.23, DLD1 0.7 ± 0.22, and HT29 3.09 ± 0.39 µg/ml. Results shown are mean and SD of three independent experiments, each with three replicates. IC50 values were determined by fitting a sigmoidal dose-response curve to the data using Graph Pad Prism. HCT116, DLD1, and HT29 cells were seeded at a 60–70% confluence, the cells were treated with 0.5 µg/ml 5-FU for 0, 6, 18, 24, and 48 h. Cells were trypsinised and harvested at the indicated time points for ( C ) RT-PCR and ( D ) western blot. Gene expression was quantified using a standard curve and normalised to the housekeeping gene L19. This HCT116 FOXM1, TYMS and E2F1 mRNA levels at 48 h. Error Bars represent standard deviation. Statistical significance was determined by student’s T-test (*p value < 0.05 0 h versus 48 h in HCT116 cells). The mRNA patterns were reflected in protein expression as shown in Western blots.

Article Snippet: FOXM1 and TS immunoreactivity was evaluated on TMA sections using polyclonal rabbit anti-human FOXM1 (C20) antibody (Santa Cruz Biotechnology) and TS antibody (Abcam) in a modification of the antigen retrieval technique of Shi et al . .

Techniques: Staining, Expressing, Sulforhodamine B Assay, Reverse Transcription Polymerase Chain Reaction, Western Blot, Gene Expression, Standard Deviation

Journal: Scientific Reports

Article Title: FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression

doi: 10.1038/s41598-018-38017-0

Figure Lengend Snippet: Overexpression of FOXM1 increases chemo-resistance to 5-FU. ( A ) HCT116 cells were transiently transfected with SiFOXM1 or FOXM1 pcDNA3 plasmid, after 48 h transfection cells were harvested and probed for FOXM1 by Western blotting. ( B ) HCT116 cells were transiently transfected with SiFOXM1 and FOXM1 pcDNA3 plasmid. After 48 h transfection cells were harvested and seeded in 96 well plate and treated with 5-FU for 72 h. Overexpressed FOXM1 increases chemoresistance in HCT116 cells measured using SRB assays, whereas SiFOXM1 HCT116 cells were more sensitive to treatment. Over-expression of FOXM1 is associated with increased TYMS mRNA ( C ) levels and protein expression ( D ) but did not affect E2F1. ( E ) HCT116 cells with acquired resistance to 5-FU (HCT116 5-FU Res) have higher basal expression of FOXM1 and TYMS compared to wild-type HCT116 cells, TYMS and FOXM1 remain elevated in the resistant cell line following treatment with 0.5 µg/ml of 5-FU. F) The IC50s show a 10 fold difference in sensitivity to 5-FU between the two cell lines (mean IC50, 0.54 μg/ml ± SD 0.03, n = 2) and HCT116 5-FU Res cells (mean IC50, 5.33 μg/ml ± SD 0.30, n = 3).

Article Snippet: FOXM1 and TS immunoreactivity was evaluated on TMA sections using polyclonal rabbit anti-human FOXM1 (C20) antibody (Santa Cruz Biotechnology) and TS antibody (Abcam) in a modification of the antigen retrieval technique of Shi et al . .

Techniques: Over Expression, Transfection, Plasmid Preparation, Western Blot, Expressing

Journal: Scientific Reports

Article Title: FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression

doi: 10.1038/s41598-018-38017-0

Figure Lengend Snippet: FOXM1 regulates TYMS in colon cancer. ( A ) Cells were treated with the FOXM1 inhibitor thiostrepton to detect cell viability. HCT116 IC50-0.65 ± 0.37 μM, DLD1 IC50-1.43 ± 0.02 μM, HT29 IC50-2.1 ± 0.98 μM. ( B , C ) HCT116, DLD1, and HT29 colon cancer cells were treated with 2 µM of thiostrepton for 0, 24, 48, and 72 h; cells were trypsinised and harvested at the time points indicated for western blot analysis and RT-PCR. ( A ) Protein lysates were prepared and expression levels were analysed by western blotting using antibodies for FOXM1, E2F1, TYMS and TK-1. β-tubulin was used as a loading control. mRNA expression indicates a significant decrease in FOXM1, TYMS, E2F1 and TK-1 levels ( B – E ) at 72 h. Error Bars represent standard deviation. Statistical significance was determined by student’s T-test. (*p value < 0.05 versus control).

Article Snippet: FOXM1 and TS immunoreactivity was evaluated on TMA sections using polyclonal rabbit anti-human FOXM1 (C20) antibody (Santa Cruz Biotechnology) and TS antibody (Abcam) in a modification of the antigen retrieval technique of Shi et al . .

Techniques: Western Blot, Reverse Transcription Polymerase Chain Reaction, Expressing, Control, Standard Deviation

Journal: Scientific Reports

Article Title: FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression

doi: 10.1038/s41598-018-38017-0

Figure Lengend Snippet: FOXM1 binding site on Thymidylate Synthase (TYMS) promoter region. ( A ) Schematic representation of FOXM1 binding sites in 0 to 2000 bp upstream of TYMS transcription start site (TSS). ChIP for FOXM1 was done followed by RT PCR to analyses the binding in the TYMS promoter region in HCT116 ( B ), DLD1 ( C ), HCT116 5-FU res ( D ) cell lines. Enrichment of FOXM1 at the TYMS promoter (0–2000 bp upstream) and no enrichment observed in the control (2000–4000 bp). Thiostrepton treatment significantly down-regulates FOXM1 binding on TYMS promoter. These experiments were done in triplicate. Error Bars represent standard deviation. Statistical significance was determined by 2 way annova using graph pad prism. (P value < 0.001).

Article Snippet: FOXM1 and TS immunoreactivity was evaluated on TMA sections using polyclonal rabbit anti-human FOXM1 (C20) antibody (Santa Cruz Biotechnology) and TS antibody (Abcam) in a modification of the antigen retrieval technique of Shi et al . .

Techniques: Binding Assay, Reverse Transcription Polymerase Chain Reaction, Control, Standard Deviation

Journal: Scientific Reports

Article Title: FOXM1 modulates 5-FU resistance in colorectal cancer through regulating TYMS expression

doi: 10.1038/s41598-018-38017-0

Figure Lengend Snippet: Genome wide distribution of FOXM1 binding in HCT116 cells. ( A ) Venn diagram representing the shared FOXM1 peaks between HCT116 and DLD1 cells. ( B ) Graphs displaying statistics about the association of input genomic regions to the TSS of all the genes putatively regulated by the genomic regions. The ‘Number of associated genes per region’ graph shows how many genes each genomic region is assigned as putatively regulating based on the association rule used. ( C ) The distance to TSS graphs show the distance between input regions and their putatively regulated genes. The distances are divided into four separate bins: one from 0 to 5 kb, another from 5 kb to 50 kb, a third from 50 kb to 500 kb, and a final bin of all associations over 500 Kb. ( D ) Heat map showing FOXM1 binding events in HCT116 (right) and DLD1 (left) and HCT116 DLD1 shared reads. Heatmap was generated using ChAsE (Chromatin Analysis and Exploration) platform. Settings (peak extensions 5 kb upstream and 5 kb downstream of the peak summit and bin size 50 (bp). ( E ) The Integrative Genomics Viewer (IGV) browser was used to visualise the FOXM1 binding in down-stream targets. The input track has been subtracted from the data shown above. Blue peaks represent FOXM1 enrichment in 5-FU targets: TYMS, TYMP, and TK-1. ( F ) To confirm the IGV ChIP-seq data of FOXM1 binding, RT-PCR was carried out on HCT116 ( A ) and DLD1 ( B ) cells. The result shows FOXM1 binding on TK-1, TYMP, E2F1, E2F2, MMP2, and MLH1. P38, which is not a FOXM1 regulator, does not show any FOXM1 enrichment.

Article Snippet: FOXM1 and TS immunoreactivity was evaluated on TMA sections using polyclonal rabbit anti-human FOXM1 (C20) antibody (Santa Cruz Biotechnology) and TS antibody (Abcam) in a modification of the antigen retrieval technique of Shi et al . .

Techniques: Genome Wide, Binding Assay, Generated, ChIP-sequencing, Reverse Transcription Polymerase Chain Reaction

Journal: OncoTargets and Therapy

Article Title: Expression and functional characterization of FOXM1 in non-small cell lung cancer

doi: 10.2147/ott.s162523

Figure Lengend Snippet: Figure 1 The FOXM1 protein was detected in NSCLC tissues by immunohistochemistry (×100). Notes: (A) FOXM1-positive expression in adenocarcinoma; (B) FOXM1-positive expression in squamous cell carcinoma; (C) adenocarcinoma without FOXM1 expression; and (D) squamous cell carcinoma without FOXM1 expression. Abbreviation: NSCLC, non-small cell lung carcinoma.

Article Snippet: The sections were then washed thoroughly with phosphate buffered saline (PBS) and incubated with a rabbit anti-human FOXM1 polyclonal antibody (1:100, Proteintech Group, Inc., Rosemont, IL, USA).

Techniques: Immunohistochemistry, Expressing

Journal: OncoTargets and Therapy

Article Title: Expression and functional characterization of FOXM1 in non-small cell lung cancer

doi: 10.2147/ott.s162523

Figure Lengend Snippet: Figure 2 Survival analysis of 128 NSCLC patients. Notes: (A) Differentiation, (B) LN metastasis, (C) TNM stage, and (D) FOXM1 expression. Abbreviations: NSCLC, non-small cell lung carcinoma; LN, lymph node; TNM, tumor-node-metastasis.

Article Snippet: The sections were then washed thoroughly with phosphate buffered saline (PBS) and incubated with a rabbit anti-human FOXM1 polyclonal antibody (1:100, Proteintech Group, Inc., Rosemont, IL, USA).

Techniques: Expressing

Journal: OncoTargets and Therapy

Article Title: Expression and functional characterization of FOXM1 in non-small cell lung cancer

doi: 10.2147/ott.s162523

Figure Lengend Snippet: Figure 3 The FOXM1 expression in NSCLC cell lines and their biological functions. Notes: (A) The FOXM1 expression in NSCLC cell lines and normal bronchial epithelial cell line HBE was detected by Western blot (left) and ELISA (right). Western blot (B) and ELISA (C) verified the efficiency of FOXM1 overexpression and knockdown in NSCLC cell lines. (D) The FOXM1 overexpression enhanced proliferation of NSCLC cell lines. (E) The FOXM1 overexpression promoted invasion of NSCLC cell lines. (*P,0.05; the t-test was used to contrast quantitative variables between groups). Abbreviations: NSCLC, non-small-cell lung carcinoma; LN, lymph node; TNM, tumor-node-metastasis.

Article Snippet: The sections were then washed thoroughly with phosphate buffered saline (PBS) and incubated with a rabbit anti-human FOXM1 polyclonal antibody (1:100, Proteintech Group, Inc., Rosemont, IL, USA).

Techniques: Expressing, Western Blot, Enzyme-linked Immunosorbent Assay, Over Expression, Knockdown